1 day Ago By Defense World Staff
Arrowstreet Capital Limited Partnership decreased its holdings in Anika Therapeutics, Inc. ( NASDAQ:ANIK – Free Report ) by 45.4% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission.
The institutional investor owned 59,455 shares of the biotechnology company’s stock after selling 49,338 shares during the quarter. Arrowstreet Capital Limited Partnership owned 0.41% of Anika Therapeutics worth $979,000 at the end of the most recent reporting period.
A number of other large investors have also recently bought and sold shares of the company. JPMorgan Chase & Co. lifted its holdings in shares of Anika Therapeutics by 431.
9% in the fourth quarter. JPMorgan Chase & Co. now owns 82,491 shares of the biotechnology company’s stock worth $1,358,000 after acquiring an additional 66,982 shares during the last quarter.
Capital Management Corp VA boosted its position in Anika Therapeutics by 12.1% in the fourth quarter. Capital Management Corp VA now owns 325,545 shares of the biotechnology company’s stock valued at $5,358,000 after buying an additional 35,195 shares in the last quarter.
Barclays PLC grew its stake in shares of Anika Therapeutics by 66.6% during the third quarter. Barclays PLC now owns 32,664 shares of the biotechnology company’s stock worth $806,000 after buying an additional 13,054 shares during the last quarter.
Bank of New York Mellon Corp lifted its stake in shares of Anika Therapeutics by 20.8% in the 4th quarter. Bank of New York Mellon Corp now owns 50,529 shares of the biotechnology company’s stock valued at $832,000 after acquiring an additional 8,711 shares during the last quarter.
Finally, Jane Street Group LLC boosted its holdings in shares of Anika Therapeutics by 54.1% during the 3rd quarter. Jane Street Group LLC now owns 24,351 shares of the biotechnology company’s stock valued at $601,000 after acquiring an additional 8,550 shares in the last quarter.
91.53% of the stock is currently owned by institutional investors and hedge funds. Wall Street Analysts Forecast Growth A number of analysts have recently commented on ANIK shares.
StockNews.com raised Anika Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, March 13th. Barrington Research reduced their price objective on shares of Anika Therapeutics from $25.
00 to $20.00 and set an “outperform” rating on the stock in a research note on Thursday, March 13th. Anika Therapeutics Stock Performance Anika Therapeutics stock opened at $13.
64 on Friday. The stock’s 50 day moving average price is $16.19 and its two-hundred day moving average price is $17.
98. The stock has a market capitalization of $193.36 million, a price-to-earnings ratio of -2.
05 and a beta of 0.82. Anika Therapeutics, Inc.
has a 52-week low of $12.83 and a 52-week high of $29.12.
Anika Therapeutics ( NASDAQ:ANIK – Get Free Report ) last announced its quarterly earnings results on Wednesday, March 12th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.
01) by ($0.13). Anika Therapeutics had a negative return on equity of 2.
22% and a negative net margin of 59.40%. The firm had revenue of $30.
60 million during the quarter, compared to the consensus estimate of $29.00 million. On average, equities research analysts forecast that Anika Therapeutics, Inc.
will post -0.84 EPS for the current year. Anika Therapeutics Profile ( Free Report ) Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.
See Also Five stocks we like better than Anika Therapeutics Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours? Robinhood Strategies Could Be a Game-Changer for Young Investors What is a buyback in stocks? A comprehensive guide for investors Are These 3 Retail Stocks Oversold or Really in Trouble? How to Profit From Value Investing IONQ & RGTI Join DARPA Quantum Initiative: High Stakes Are Ahead Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
